British Biotech plc Research Director.Business & Health Editors OXFORD, England--(BUSINESS WIRE)--March 16, 2000 British Biotech British Biotech was a British based biotech company. British Biotechnology Limited was founded in 1986 by former G D Searle managers Keith McCullagh and Brian Richards, [1] (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :BBIOY) announced today that Dr Alan Drummond has resigned as Research Director with effect from March 17, 2000. Dr Giles Campion campion: see pink. campion Any of the ornamental rock-garden or border plants that make up the genus Silene, of the pink family, consisting of about 500 species of herbaceous plants found throughout the world. , currently Development Director and Chief Medical Officer, will assume responsibility for all research and development activities as Research and Development Director and Chief Medical Officer. British Biotech is building a portfolio of products for the treatment of cancer, infection and inflammation inflammation, reaction of the body to injury or to infectious, allergic, or chemical irritation. The symptoms are redness, swelling, heat, and pain resulting from dilation of the blood vessels in the affected part with loss of plasma and leucocytes (white blood . These opportunities will be generated from in-house In-house In the context of general equities, keeping an activity within the firm. For example, rather than go to the marketplace and sell a security for a client to anyone, an attempt is made to find a buyer to complete the transaction with the firm. research and development and by acquisition from, and collaboration with, outside parties. The organization has been aligned behind this strategy through the creation of Corporate Project Teams, integrating representatives from all areas of the business, to deliver value over the next three years. Commenting on today's announcement, Mr Chris Hampson, Chairman, British Biotech plc, said: "The Board would like to thank Alan Drummond for his outstanding contribution to the Company over the last 12 years. During this period his leadership has established British Biotech's strength and expertise in metalloenzymes and their inhibition inhibition In enzymology, a phenomenon in which a compound (an inhibitor), usually similar in structure to the substance on which an enzyme acts (substrate), interacts with the enzyme so that the resulting complex cannot undergo the usual reaction or cannot form the usual . We are sorry to see him leave and wish him well for the future. The organizational changes enhance our ability to build value in the business as we move forward. Giles Campion has a strong track record in pharmaceutical research and development with substantial experience leading integrated projects." Dr Alan Drummond, said: "I am pleased to have contributed to bringing British Biotech's discovery and research base to its current position. With this greater integration across the business, I feel it is time to pursue my career elsewhere." This news release contains forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. which reflect the Company's current expectation regarding future events. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors including the success of the Company's research strategy, the applicability of the discoveries made therein, the successful and timely completion of clinical studies and the uncertainties related to the regulatory process. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion